For R/R ALL and NHL, bispecific CD19/CD20 and CD19/CD22 CARs are currently in clinical trials but preliminary results demonstrated good efficacy with favorable safety profile [86,87,88,89]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.